[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363971-105":59,"doc-detail-363971-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomic-biomarker-discovery-in-breast-cancer-advances-challenges-and-translational-prospects","Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects","","Breast cancer remains a leading cause of cancer-related morbidity and mortality among women worldwide. Despite major progress in genomic classification, molecular pathology, and targeted therapy, clinically reliable proteomics-derived biomarkers for early detection, prognostic stratification, treatment response prediction, and longitudinal monitoring are still not fully resolved. Proteomic profiling of breast cancer tissues and accessible biofluids has generated candidate protein signatures. LC-MS/MS and advanced quantification platforms improve depth and scalability, yet limitations in sensitivity, specificity, cohort size, external validation, and clinical utility continue to hinder translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomic-biomarker-discovery-in-breast-cancer-advances-challenges-and-translational-prospects/363971/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomic-biomarker-discovery-in-breast-cancer-advances-challenges-and-translational-prospects/363971.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are proteomics-derived biomarkers for breast cancer still challenging to translate clinically?","Question",{"text":112,"@type":113},"Many candidates remain in discovery or early verification because of limited analytical sensitivity, insufficient specificity, inter-platform variability, small heterogeneous cohorts, and incomplete external validation, creating uncertainty about clinical utility beyond established pathology markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of samples are commonly used for proteomic biomarker discovery in breast cancer?",{"text":117,"@type":113},"Research uses both breast cancer tissues and clinically accessible biofluids, including serum, plasma, saliva, nipple aspirate fluid, urine, and extracellular vesicle–enriched fractions.",{"name":119,"@type":110,"acceptedAnswer":120},"What major proteomic technologies are highlighted for biomarker research?",{"text":121,"@type":113},"Platforms include LC-MS/MS, data-independent acquisition mass spectrometry, multiplexed quantitative proteomics, targeted proteomics (MRM/PRM), spatial proteomics, and high-throughput affinity-based assays such as Olink and SomaScan.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363971,1790363348,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of Biochemical and Molecular Toxicology   \n REVIEW   \nProteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects  \nMahan Hassani1 | Iman Morshedi2 | K. J. Matmurotov3 | Isanova Shoira Tulkinovna4  |  \nAbdullaev Makhmudjon Mukhamedovich5 | Mahdieh Khorsandi6 | Abdiyev Rasul Ernazar Ugli5  | Tianyao Yang7 | Xi Lin7  \n1School of Pharmacy, Near East University of North Cyprus, Nicosia, Cyprus | 2Faculty of Pharmacy, Tehran Medical Branch, Islamic Azad University, Tehran, Iran | 3Dotsent of the Department of “General and Pediatric Surgery”, Tashkent State Medical University, Tashkent, Uzbekistan | 4Department of Neurology, Samarkand State Medical University, Samarkand, Uzbekistan | 5Department of Mechatronics and Robotics, Faculty of Electronics and Automation, Tashkent State Technical University named after Islam Karimov, Tashkent, Uzbekistan | 6Department of Biotechnology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | 7Department of Thyroid, Breast & Hernia Surgery, Tiantai People's Hospital of Zhejiang Province (Tiantai Branch of Zhejiang Provincial People's Hospital), Taizhou, Zhejiang, China  \nCorrespondence: Tianyao Yang ([ytyttyang1045@163.com](ytyttyang1045@163.com))  \nReceived: 20 April 2025 | Revised: 17 June 2026 | Accepted: 23 July 2026  \nKeywords: biomarker validation | breast cancer | clinical translation | mass spectrometry | protein biomarkers | proteomics  \nABSTRACT  \nBreast cancer remains a leading cause of cancer‐related morbidity and mortality among women worldwide. Despite major progress in genomic classification, molecular pathology, and targeted therapy, the identification of clinically reliable proteomics‐derived biomarkers for early detection, prognostic stratification, treatment response prediction, and longitudinal monitoring remains an unresolved translational challenge. Recent studies have applied proteomic profiling to breast cancer tissues and clinically accessible biofluids, including serum, plasma, saliva, nipple aspirate fluid, urine, and extracellular vesicle‐ enriched fractions, to identify protein signatures with potential diagnostic and therapeutic relevance. Contemporary platforms, including LC‐MS/MS, data‐independent acquisition mass spectrometry, multiplexed quantitative proteomics, targeted proteomics using multiple reaction monitoring and parallel reaction monitoring, spatial proteomics, and affinity‐based high‐ throughput assays such as Olink and SomaScan, have expanded the analytical depth and clinical scalability of breast cancer biomarker research. However, many candidate biomarkers remain confined to discovery or early verification stages because of limited analytical sensitivity, insufficient specificity, inter‐platform variability, small and heterogeneous cohorts, incomplete external validation, and uncertainty regarding clinical utility beyond established pathological markers. This review critically evaluates current proteomic technologies and proteomics‐derived biomarker candidates in breast cancer, distinguishes discovery‐level findings from clinically validated evidence, and discusses the major methodological, regulatory, and implementation barriers that continue to limit translation into routine oncology practice. Greater emphasis on standardized workflows, targeted verification, multi‐center validation, and clinically actionable biomarker panels will be essential for integrating proteomics into precision breast cancer care.  \n\n| Abbreviations: AR, Androgen receptor; DFS, disease‐free survival; DHT, Dihydrotestosterone; EGFR, Epidermal growth factor receptor; ELISA, Enzyme‐linked immunosorbent assay; ER, estrogen receptor; FASN, Fatty acid synthase; FDA, Food and Drug Administration; FDR, false discovery rate; FISH, fluorescence in situ hybridization; HE4, Human epididymis protein 4; HER2, Human epidermal growth factor receptor 2; HSP, heat shock protein; IHC, immunohistochemistry; iTRAQ, Isobaric tag","cbCaiu47xSIMxm7D","https://ap.wps.com/l/cbCaiu47xSIMxm7D","pdf",1897259,18,"English","# Introduction\n# Proteomic Biomarkers in Breast Cancer: Evidence and Validation\n## Discovery-Level Findings vs Clinically Validated Evidence\n## Key Technologies and Analytical Platforms\n# Translational Barriers and Implementation Challenges\n## Regulatory and Practical Considerations\n# Conclusion and Future Directions","[{\"question\":\"Why are proteomics-derived biomarkers for breast cancer still challenging to translate clinically?\",\"answer\":\"Many candidates remain in discovery or early verification because of limited analytical sensitivity, insufficient specificity, inter-platform variability, small heterogeneous cohorts, and incomplete external validation, creating uncertainty about clinical utility beyond established pathology markers.\"},{\"question\":\"Which types of samples are commonly used for proteomic biomarker discovery in breast cancer?\",\"answer\":\"Research uses both breast cancer tissues and clinically accessible biofluids, including serum, plasma, saliva, nipple aspirate fluid, urine, and extracellular vesicle–enriched fractions.\"},{\"question\":\"What major proteomic technologies are highlighted for biomarker research?\",\"answer\":\"Platforms include LC-MS/MS, data-independent acquisition mass spectrometry, multiplexed quantitative proteomics, targeted proteomics (MRM/PRM), spatial proteomics, and high-throughput affinity-based assays such as Olink and SomaScan.\"}]","Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects | PDF",1790154657,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ece4b3205075e31a28dc852034275d5d.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d71ed19da8964b72146432b72e2a8419.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/012a3327bc842548987fcaf591b0356f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66c7fd7bb2d90e25f6a200fe23245240.webp",980,1287]